Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
VOLITIONRX LTD (VNRX)
AMEXHealth CareMedical - DevicesSnapshot 2026-11-05
$0.19-6.94%
Close 2026-11-05 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for VNRX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Operating income improvement to reduce losses | It improved operating income by $949K. | Intact | Operating loss worsens beyond -$6.3M next quarter | Operating income: $-4.156M FY2026-Q2; GAAP. Published target: Operating loss improves to better than -$5.3M next quarter. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 13, 2026-4,155,983 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making commercialization story, not an established durable compounder. The thesis is in a watch state, with the signal recently shifting from mixed to cautious.
VNRX is described as cheap versus peers, but the model has low confidence and indicates that expectations are below the peer benchmark. The evidence also labels pricing as justified, with no identified fragility flags, so the apparent discount alone does not establish a strong valuation case.
Near term, earnings-miss risk is elevated, and a guidance cut would add pressure; recent performance is also below the industry cohort. Over the multi-year view, first-half revenue grew 112% year over year and expenses fell, while debt reduction has progressed, but quarterly product revenue was flat and licensing progress remains limited.
The multi-year thesis depends on management converting licensing efforts and Nu.Q product development into broader commercial revenue while continuing to reduce debt and expenses. Near-term results could weaken if guidance is cut or job growth deteriorates; continued strength from healthcare bellwethers could support the sector backdrop.
The business shows early revenue growth and cost-control progress, but losses, volatile execution, and elevated near-term earnings risk leave the multi-year thesis cautious. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in VOLITIONRX LTD's published investment case. The stated target is Maintain compliance with NYSE listing standards. |
| Intact |
| Fails to meet NYSE listing requirements |
Qualitative condition This condition has no defined numerical measure. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth from strategic partnerships | A primary condition in VOLITIONRX LTD's published investment case. The stated target is >= $985,076 next quarter. | Intact | Revenue falls below $191,657 next quarter | Revenue: $398,657 FY2026-Q2; GAAP. Published target: >= $985,076 next quarter. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 13, 2026398,657 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.14 → $-0.73 · observed estimates
$0.01B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-07-25 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-07-26 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-07-27 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-07-28 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-07-29 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-07-30 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-07-31 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-08-01 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-08-02 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-08-03 | $-1.15 | $5,733,330 | 1 / 3 |
| 2026-08-04 | $-1.15 | $5,733,330 | 1 / 3 |
| 2026-08-05 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-08-06 | $-1.15 | $5,733,330 | 1 / 3 |
| 2026-08-08 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-08-09 | $-1.15 | $5,733,330 | 1 / 3 |
| 2026-08-10 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-08-12 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-08-13 | $-1.15 | $5,733,330 | 1 / 3 |
| 2026-08-14 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-08-15 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-08-16 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-08-17 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-08-18 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-08-19 | $-1.14 | $5,347,750 | 2 / 3 |
| 2026-08-20 | $-0.80 | $5,002,750 | 2 / 3 |
| 2026-08-21 | $-0.80 | $5,002,750 | 2 / 3 |
| 2026-08-22 | $-0.80 | $5,002,750 | 2 / 3 |
| 2026-08-23 | $-0.80 | $5,002,750 | 2 / 3 |
| 2026-08-24 | $-0.80 | $5,002,750 | 2 / 3 |
| 2026-08-25 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-08-26 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-08-27 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-08-28 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-08-29 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-08-30 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-08-31 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-01 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-02 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-03 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-04 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-05 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-06 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-07 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-08 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-09 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-10 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-11 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-12 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-13 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-14 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-15 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-16 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-17 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-18 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-19 | $-0.73 | $3,863,667 | 2 / 3 |
| 2026-09-20 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-09-21 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-09-22 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-09-23 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-09-24 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-09-25 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-09-26 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-09-27 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-09-28 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-09-29 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-09-30 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-01 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-02 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-03 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-04 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-05 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-06 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-07 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-08 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-09 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-10 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-11 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-12 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-13 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-14 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-15 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-16 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-17 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-18 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-19 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-20 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-21 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-22 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-23 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-24 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-25 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-26 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-27 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-28 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-29 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-30 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-10-31 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-11-01 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-11-02 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-11-03 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-11-04 | $-0.73 | $3,863,667 | 2 / 4 |
| 2026-11-05 | $-0.73 | $3,863,667 | 2 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.